| Title |
Giant-cell tumor of bone: treatment options and role of denosumab
|
|---|---|
| Published in |
Biologics: Targets & Therapy, July 2015
|
| DOI | 10.2147/btt.s57359 |
| Pubmed ID | |
| Authors |
Arun S Singh, Neal S Chawla, Sant P Chawla |
| Abstract |
Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-κB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 96 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 18 | 19% |
| Student > Ph. D. Student | 12 | 13% |
| Researcher | 8 | 8% |
| Student > Bachelor | 6 | 6% |
| Other | 6 | 6% |
| Other | 19 | 20% |
| Unknown | 27 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Nursing and Health Professions | 2 | 2% |
| Agricultural and Biological Sciences | 2 | 2% |
| Other | 7 | 7% |
| Unknown | 32 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2015.
All research outputs
#16,868,837
of 25,584,565 outputs
Outputs from Biologics: Targets & Therapy
#181
of 274 outputs
Outputs of similar age
#156,496
of 277,879 outputs
Outputs of similar age from Biologics: Targets & Therapy
#2
of 4 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,879 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.